108,370 Biogen Inc. $BIIB Shares Bought by E. Ohman J or Asset Management AB

Key Points

• E. Ohman J or Asset Management AB increased its Biogen stake by 108,370 shares, or 2,248.8%, to 113,189 shares valued at approximately $25.6 million. Institutional investors collectively own 87.93% of Biogen.
• Biogen reported quarterly EPS of $3.60, exceeding the $2.94 consensus estimate, while revenue of $2.74 billion also topped expectations and rose 3.4% year over year.
• Analysts maintain a generally positive view, with a consensus rating of “Moderate Buy” and an average price target of $241.89, although the stock’s recent price near $253.84 is above that target.

E. Ohman J or Asset Management AB lifted its stake in shares of Biogen Inc. (NASDAQ:BIIB - Free Report) by 2,248.8% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 113,189 shares of the biotechnology company's stock after purchasing an additional 108,370 shares during the quarter. E. Ohman J or Asset Management AB owned about 0.08% of Biogen worth $25,567,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also made changes to their positions in the business. Forum Financial Management LP grew its holdings in shares of Biogen by 2.4% during the third quarter. Forum Financial Management LP now owns 1,936 shares of the biotechnology company's stock valued at $437,000 after buying an additional 46 shares in the last quarter. Integrated Advisors Network LLC boosted its position in Biogen by 3.5% during the third quarter. Integrated Advisors Network LLC now owns 1,403 shares of the biotechnology company's stock valued at $317,000 after purchasing an additional 48 shares during the last quarter. Wedbush Securities Inc. lifted its holdings in shares of Biogen by 5.1% during the 2nd quarter. Wedbush Securities Inc. now owns 1,164 shares of the biotechnology company's stock valued at $251,000 after buying an additional 56 shares during the last quarter. Meeder Advisory Services Inc. raised its position in Biogen by 1.2% during the first quarter. Meeder Advisory Services Inc. now owns 4,721 shares of the biotechnology company's stock valued at $866,000 after acquiring an additional 57 shares in the last quarter. Finally, Kera Capital Partners Inc. grew its position in Biogen by 3.5% in the first quarter. Kera Capital Partners Inc. now owns 1,723 shares of the biotechnology company's stock worth $316,000 after acquiring an additional 58 shares in the last quarter. 87.93% of the stock is currently owned by institutional investors.

Biogen Price Performance

Biogen stock opened at $253.84 on Friday. The business's fifty day moving average is $222.78 and its two-hundred day moving average is $205.73. Biogen Inc. has a 52 week low of $138.00 and a 52 week high of $254.41. The firm has a market cap of $37.50 billion, a P/E ratio of 44.93, a P/E/G ratio of 2.68 and a beta of 0.09. The company has a debt-to-equity ratio of 0.39, a quick ratio of 1.26 and a current ratio of 1.87.

Biogen (NASDAQ:BIIB - Get Free Report) last issued its quarterly earnings data on Wednesday, July 29th. The biotechnology company reported $3.60 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.94 by $0.66. Biogen had a net margin of 8.32% and a return on equity of 11.18%. The company had revenue of $2.74 billion during the quarter, compared to the consensus estimate of $2.46 billion. During the same quarter in the prior year, the firm earned $5.47 earnings per share. The firm's revenue was up 3.4% compared to the same quarter last year. Biogen has set its FY 2026 guidance at 12.000-13.000 EPS. Equities research analysts forecast that Biogen Inc. will post 12.31 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on the stock. Canaccord Genuity Group raised their target price on shares of Biogen from $245.00 to $248.00 and gave the company a "buy" rating in a research note on Thursday, July 30th. Weiss Ratings upgraded shares of Biogen from a "hold (c-)" rating to a "hold (c)" rating in a research note on Thursday, September 24th. Royal Bank Of Canada decreased their price target on shares of Biogen from $260.00 to $256.00 and set an "outperform" rating on the stock in a research report on Thursday, October 8th. Wolfe Research raised shares of Biogen from a "peer perform" rating to an "outperform" rating and set a $300.00 price objective for the company in a research report on Thursday, August 13th. Finally, Wells Fargo & Company upped their price target on Biogen from $250.00 to $310.00 and gave the company an "overweight" rating in a report on Tuesday. One investment analyst has rated the stock with a Strong Buy rating, nineteen have issued a Buy rating, eleven have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $241.89.

Trending Headlines about Biogen

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: Wells Fargo raised its price target on Biogen, adding to a series of upward analyst revisions and reinforcing optimism about the company’s outlook. Biogen Stock Gets Price Target Boost from Wells Fargo
• Positive Sentiment: Bank of America increased its Biogen price target to $244 from $219. Although the firm maintained a Neutral rating, the revision reflects improved expectations as analysts update their models ahead of earnings. Biogen on BofA Price Target Hike
• Positive Sentiment: Several previews suggest Biogen could exceed third-quarter earnings estimates, supported by favorable analyst expectations and the potential for continued progress across its late-stage drug pipeline. Biogen Expected to Beat Earnings Estimates
• Neutral Sentiment: Wedbush kept a Hold rating on Biogen, indicating that valuation and near-term catalysts may already be reflected in the share price. Wedbush Remains a Hold on Biogen
• Negative Sentiment: Bank of America’s $244 target remains below the stock’s recent trading level, implying limited upside or potential downside despite the target increase. Analysts also characterize the upcoming quarter as relatively quiet, and earnings previews warn that disappointment remains possible.

Biogen Company Profile

Biogen Inc is a biotechnology company that discovers, develops and commercializes therapies for neurological and neurodegenerative diseases. Its areas of focus include multiple sclerosis, Alzheimer's disease, spinal muscular atrophy, amyotrophic lateral sclerosis and other serious medical conditions.

The company's portfolio includes multiple sclerosis treatments such as Tecfidera, Vumerity, Tysabri, Plegridy and Avonex, as well as Spinraza for spinal muscular atrophy. Biogen also markets Leqembi, an Alzheimer's disease treatment developed in collaboration with Eisai, and works with partners to advance additional therapies and biosimilars.

Biogen was founded in 1978 and is headquartered in Cambridge, Massachusetts.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.